DK1601677T3 - Spirosubstituerede pyrrolopyrimidiner - Google Patents
Spirosubstituerede pyrrolopyrimidinerInfo
- Publication number
- DK1601677T3 DK1601677T3 DK04715273T DK04715273T DK1601677T3 DK 1601677 T3 DK1601677 T3 DK 1601677T3 DK 04715273 T DK04715273 T DK 04715273T DK 04715273 T DK04715273 T DK 04715273T DK 1601677 T3 DK1601677 T3 DK 1601677T3
- Authority
- DK
- Denmark
- Prior art keywords
- cathepsin
- formula
- spirosubstituted
- pyrrolopyrimidines
- compounds
- Prior art date
Links
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
- 108090000625 Cathepsin K Proteins 0.000 abstract 2
- 102000004171 Cathepsin K Human genes 0.000 abstract 2
- 108090000613 Cathepsin S Proteins 0.000 abstract 2
- 102100035654 Cathepsin S Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0304640.6A GB0304640D0 (en) | 2003-02-28 | 2003-02-28 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1601677T3 true DK1601677T3 (da) | 2006-10-30 |
Family
ID=9953876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04715273T DK1601677T3 (da) | 2003-02-28 | 2004-02-27 | Spirosubstituerede pyrrolopyrimidiner |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7531546B2 (da) |
| EP (1) | EP1601677B1 (da) |
| JP (1) | JP2006519207A (da) |
| CN (1) | CN100341876C (da) |
| AT (1) | ATE331718T1 (da) |
| AU (1) | AU2004215648B2 (da) |
| BR (1) | BRPI0407919A (da) |
| CA (1) | CA2517035A1 (da) |
| CY (1) | CY1105637T1 (da) |
| DE (1) | DE602004001397T2 (da) |
| DK (1) | DK1601677T3 (da) |
| ES (1) | ES2268633T3 (da) |
| GB (1) | GB0304640D0 (da) |
| MX (1) | MXPA05009157A (da) |
| PL (1) | PL378469A1 (da) |
| PT (1) | PT1601677E (da) |
| WO (1) | WO2004076455A1 (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| WO2007028638A1 (en) | 2005-09-09 | 2007-03-15 | Euro-Celtique S.A. | Fused and spirocycle compounds and the use thereof |
| EP1957494A2 (en) * | 2005-12-05 | 2008-08-20 | Incyte Corporation | Lactam compounds and methods of using the same |
| US20080269241A1 (en) * | 2007-02-15 | 2008-10-30 | Darin Allen | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20090099157A1 (en) * | 2007-02-15 | 2009-04-16 | Ameriks Michael K | Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s |
| US20080200454A1 (en) * | 2007-02-15 | 2008-08-21 | Ameriks Michael K | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20090118274A1 (en) * | 2007-02-15 | 2009-05-07 | Darin Allen | Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20080207683A1 (en) * | 2007-02-15 | 2008-08-28 | Darin Allen | Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| EP2160187B1 (en) * | 2007-05-16 | 2013-05-22 | Merck Sharp & Dohme Corp. | Spiroindalones |
| CA2978149C (en) | 2008-03-21 | 2019-02-12 | The General Hospital Corporation | Inositol derivatives for the detection and treatment of alzheimer's disease and related disorders |
| CN104945420A (zh) | 2009-06-29 | 2015-09-30 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| KR102507287B1 (ko) | 2011-09-02 | 2023-03-07 | 인사이트 홀딩스 코포레이션 | Pi3k 억제제로서 헤테로시클릴아민 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| ES2644965T3 (es) * | 2012-04-17 | 2017-12-01 | Astellas Pharma Inc. | Compuesto heterocíclico aromático bicíclico nitrogenado |
| BR112015008325B1 (pt) * | 2012-10-16 | 2022-01-25 | Janssen Sciences Ireland Uc | Compostos antivirais contra o rsv, seu uso e composição farmacêutica que os compreende |
| WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
| TWI671299B (zh) | 2014-04-14 | 2019-09-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 作為rsv抗病毒化合物之螺脲化合物 |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| SI3831833T1 (sl) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
| US10537552B2 (en) | 2015-05-05 | 2020-01-21 | Carafe Drug Innovation, Llc | Substituted 5-hydroxyoxindoles and their use as analgesics and fever reducers |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| CN107935908A (zh) * | 2016-10-12 | 2018-04-20 | 上海科胜药物研发有限公司 | 一种尼达尼布(nintedanib)的制备方法及其中间体 |
| AU2019243099B2 (en) | 2018-03-28 | 2022-04-07 | Hanlim Pharmaceutical Co., Ltd. | 2-cyanopyrimidin-4-yl carbamate or urea derivative or salt thereof, and pharmaceutical composition including same |
| CA3101323A1 (en) | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
| EP4608839A1 (en) * | 2022-10-26 | 2025-09-03 | Protego Biopharma, Inc. | Spirocycle containing bicyclic heteroaryl compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001247589A1 (en) * | 2000-03-20 | 2001-10-03 | Axys Pharmaceuticals, Inc. | Non-amidine containing protease inhibitors |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR043692A1 (es) * | 2003-02-06 | 2005-08-10 | Novartis Ag | 2-cianopirrolopirimidinas y sus usos farmaceuticos |
-
2003
- 2003-02-28 GB GBGB0304640.6A patent/GB0304640D0/en not_active Ceased
-
2004
- 2004-02-27 AT AT04715273T patent/ATE331718T1/de not_active IP Right Cessation
- 2004-02-27 DE DE602004001397T patent/DE602004001397T2/de not_active Expired - Fee Related
- 2004-02-27 CN CNB2004800054716A patent/CN100341876C/zh not_active Expired - Fee Related
- 2004-02-27 BR BRPI0407919-1A patent/BRPI0407919A/pt not_active IP Right Cessation
- 2004-02-27 PT PT04715273T patent/PT1601677E/pt unknown
- 2004-02-27 JP JP2006501973A patent/JP2006519207A/ja active Pending
- 2004-02-27 WO PCT/EP2004/001982 patent/WO2004076455A1/en not_active Ceased
- 2004-02-27 US US10/547,184 patent/US7531546B2/en not_active Expired - Fee Related
- 2004-02-27 AU AU2004215648A patent/AU2004215648B2/en not_active Ceased
- 2004-02-27 EP EP04715273A patent/EP1601677B1/en not_active Expired - Lifetime
- 2004-02-27 PL PL378469A patent/PL378469A1/pl not_active Application Discontinuation
- 2004-02-27 ES ES04715273T patent/ES2268633T3/es not_active Expired - Lifetime
- 2004-02-27 MX MXPA05009157A patent/MXPA05009157A/es active IP Right Grant
- 2004-02-27 DK DK04715273T patent/DK1601677T3/da active
- 2004-02-27 CA CA002517035A patent/CA2517035A1/en not_active Abandoned
-
2006
- 2006-09-28 CY CY20061101408T patent/CY1105637T1/el unknown
-
2009
- 2009-03-30 US US12/413,996 patent/US20090186889A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB0304640D0 (en) | 2003-04-02 |
| DE602004001397D1 (de) | 2006-08-10 |
| HK1089156A1 (en) | 2006-11-24 |
| CA2517035A1 (en) | 2004-09-10 |
| BRPI0407919A (pt) | 2006-03-01 |
| MXPA05009157A (es) | 2005-10-20 |
| EP1601677A1 (en) | 2005-12-07 |
| AU2004215648B2 (en) | 2007-10-11 |
| ATE331718T1 (de) | 2006-07-15 |
| DE602004001397T2 (de) | 2007-04-26 |
| CN100341876C (zh) | 2007-10-10 |
| ES2268633T3 (es) | 2007-03-16 |
| PL378469A1 (pl) | 2006-04-03 |
| JP2006519207A (ja) | 2006-08-24 |
| US20060258690A1 (en) | 2006-11-16 |
| AU2004215648A1 (en) | 2004-09-10 |
| EP1601677B1 (en) | 2006-06-28 |
| CN1753895A (zh) | 2006-03-29 |
| WO2004076455A1 (en) | 2004-09-10 |
| PT1601677E (pt) | 2006-11-30 |
| US20090186889A1 (en) | 2009-07-23 |
| CY1105637T1 (el) | 2010-12-22 |
| US7531546B2 (en) | 2009-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1601677T3 (da) | Spirosubstituerede pyrrolopyrimidiner | |
| GB0220187D0 (en) | Organic compounds | |
| GB0121033D0 (en) | Organic compounds | |
| MXPA04001930A (es) | Inhibidores de proteasa de cisteina con estructura de 2-ciano-4amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflaciones y otras enfermedades. | |
| NO20044038L (no) | Glutaminylbaserte DRIV-inhibitorer | |
| EP2295433A3 (en) | JNK inhibitors | |
| GB0223040D0 (en) | Therapeutic compounds | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| ITMI20031311A1 (it) | Formulazioni per il trattamento di disturbi artrosici. | |
| MXPA05007607A (es) | Inhibidores amida y ester de la metaloproteinasa de matriz. | |
| PT1606288E (pt) | Derivados de benzenossulfonamida, processo para a sua preparação e a sua utilização para tratamento da dor | |
| SE0002739D0 (sv) | New use | |
| IS8498A (is) | Notkun katepsín K tálma til að meðhöndla alvarlega beintapssjúkdóma | |
| ECSP044989A (es) | Inhibidores de proteasa de cisteina con estructura de 2-ciano-4-amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflamaciones y otras enfermedades | |
| MXPA05006296A (es) | Uso de tiazolobenzoheterociclos para el tratamiento de la esclerosis multiple. | |
| DE502004007517D1 (de) | Anti-apoptotisch wirksame apatamere | |
| MY140242A (en) | BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS | |
| ITFI20030292A1 (it) | Strumento chirurgico ortopedico per l'applicazione di | |
| DOP2003000728A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenetivos |